Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?

References

• Ravi V, Patel S. Vascular sarcomas. Curr Oncol Rep. 2013;15(4):347–355. doi:10.1007/s11912-013-0328-2
   PubMed Web of Science ®Google Scholar
• Lee SJ, Yang WI, Chung WS, et al. Epithelioid hemangioendotheliomas with TFE3 gene translocations are compossible with CAMTA1 gene rearrangements. Oncotarget. 2016;7(7):7480–7488. doi:10.18632/oncotarget.7060
   PubMedGoogle Scholar
• Errani C, Zhang L, Sung YS, et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer. 2011;50(8):644–653. doi:10.1002/gcc.20886
   PubMed Web of Science ®Google Scholar
• Tanas MR, Sboner A, Oliveira AM, et al. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med. 2011;3(98):98ra82. doi:10.1126/scitranslmed.3002409
   PubMed Web of Science ®Google Scholar
• Lamar JM, Motilal Nehru V, Weinberg G. Epithelioid hemangioendothelioma as a model of YAP/TAZ-driven cancer: insights from a rare fusion sarcoma. Cancers (Basel). 2018;10:7. doi:10.3390/cancers10070229
   PubMed Web of Science ®Google Scholar
• Smoot RL, Werneburg NW, Sugihara T, et al. Platelet-derived growth factor regulates YAP transcriptional activity via Src family kinase dependent tyrosine phosphorylation. J Cell Biochem. 2018;119(1):824–836. doi:10.1002/jcb.26246
   PubMed Web of Science ®Google Scholar
• Konstantinidis IT, Nota C, Jutric Z, et al. Primary liver sarcomas in the modern era: resection or transplantation? J Surg Oncol. 2018;117(5):886–891. doi:10.1002/jso.24979
   PubMed Web of Science ®Google Scholar
• Agrawal N, Parajuli S, Zhao P, et al. Liver transplantation in the management of hepatic epithelioid hemangioendothelioma: a single-center experience and review of the literature. Transplant Proc. 2011;43(7):2647–2650. doi:10.1016/j.transproceed.2011.06.035
   PubMed Web of Science ®Google Scholar
• Thomas RM, Aloia TA, Truty MJ, et al. Treatment sequencing strategy for hepatic epithelioid haemangioendothelioma. HPB (Oxford). 2014;16(7):677–685. doi:10.1111/hpb.12202
   PubMed Web of Science ®Google Scholar
• Yousaf N, Maruzzo M, Judson I, et al. Systemic treatment options for epithelioid haemangioendothelioma: the Royal Marsden Hospital experience. Anticancer Res. 2015;35(1):473–480.
   PubMed Web of Science ®Google Scholar
• von Mehren M, Randall RL, Benjamin RS, et al. Soft tissue sarcoma, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(5):536–563. doi:10.6004/jnccn.2018.0025
   PubMed Web of Science ®Google Scholar
• Casali PG, Abecassis N, Bauer S, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Supplement_4):iv51–iv67. doi:10.1093/annonc/mdy096
   PubMed Web of Science ®Google Scholar
• Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised Phase 2 trial. Lancet. 2016;388(10043):488–497. doi:10.1016/S0140-6736(16)30587-6
   PubMed Web of Science ®Google Scholar
• Tap WD, Wagner AJ, Papai Z, et al. ANNOUNCE: a randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS). J Clin Oncol. 2019;37(suppl; abstr LBA3). doi:10.1200/JCO.2019.37.18_suppl.LBA3
   PubMed Web of Science ®Google Scholar
• Remiszewski P, Szczerba E, Kalinowski P, et al. Epithelioid hemangioendothelioma of the liver as a rare indication for liver transplantation. World J Gastroenterol. 2014;20(32):11333–11339. doi:10.3748/wjg.v20.i32.11333
   PubMed Web of Science ®Google Scholar
• Lai Q, Feys E, Karam V, et al. Hepatic epithelioid hemangioendothelioma and adult liver transplantation: proposal for a prognostic score based on the analysis of the ELTR-ELITA registry. Transplantation. 2017;101(3):555–564. doi:10.1097/TP.0000000000001603
   PubMed Web of Science ®Google Scholar
• Jung DH, Hwang S, Hong SM, et al. Clinicopathological features and prognosis of hepatic epithelioid hemangioendothelioma after liver resection and transplantation. Ann Transplant. 2016;21:784–790. doi:10.12659/AOT.901172
   PubMed Web of Science ®Google Scholar
• Ye B, Li W, Feng J, et al. Treatment of pulmonary epithelioid hemangioendothelioma with combination chemotherapy: report of three cases and review of the literature. Oncol Lett. 2013;5(5):1491–1496. doi:10.3892/ol.2013.1217
   PubMed Web of Science ®Google Scholar
• Kelly H, O’Neil BH. Response of epithelioid haemangioendothelioma to liposomal doxorubicin. Lancet Oncol. 2005;6(10):813–815. doi:10.1016/S1470-2045(05)70392-2
   PubMed Web of Science ®Google Scholar
• Treska V, Daum O, Svajdler M, et al. Hepatic epithelioid hemangioendothelioma - a rare tumor and diagnostic dilemma. In Vivo. 2017;31(4):763–767. doi:10.21873/invivo.11128
   PubMed Web of Science ®Google Scholar
• Gurung S, Fu H, Zhang WW, et al. Hepatic epithelioid hemangioendothelioma metastasized to the peritoneum, omentum and mesentery: a case report. Int J Clin Exp Pathol. 2015;8(5):5883–5889.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Chung MJ, Jeong KC, et al. Pleural epithelioid hemangioendothelioma. Yonsei Med J. 2008;49(6):1036–1040. doi:10.3349/ymj.2008.49.6.1036
   PubMed Web of Science ®Google Scholar
• Tolkach Y, Petrov S, Lerut E, et al. Epithelioid hemangioendothelioma of the kidney treated with sunitinib. Onkologie. 2012;35(6):376–378. doi:10.1159/000338944
   PubMedGoogle Scholar
• Saada E, Saint Paul MC, Gugenheim J, et al. Metastatic hepatic epithelioid hemangio-endothelioma: long-term response to sunitinib malate. Oncol Res Treat. 2014;37(3):124–126. doi:10.1159/000360208
   PubMed Web of Science ®Google Scholar
• Chevreau C, Le Cesne A, Ray-Coquard I, et al. Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO). Cancer. 2013;119(14):2639–2644. doi:10.1002/cncr.28109
   PubMed Web of Science ®Google Scholar
• Kollar A, Jones RL, Stacchiotti S, et al. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. Acta Oncol. 2017;56(1):88–92. doi:10.1080/0284186X.2016.1234068
   PubMed Web of Science ®Google Scholar
• Semenisty V, Naroditsky I, Keidar Z, et al. Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma-a suitable treatment option: case report and review of anti-angiogenic treatment options. BMC Cancer. 2015;15:402. doi:10.1186/s12885-015-1395-6
   PubMed Web of Science ®Google Scholar
• Zheng Z, Wang H, Jiang H, et al. Apatinib for the treatment of pulmonary epithelioid hemangioendothelioma: a case report and literature review. Medicine (Baltimore). 2017;96(45):e8507. doi:10.1097/MD.0000000000008507
   PubMed Web of Science ®Google Scholar
• Agulnik M, Yarber JL, Okuno SH, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013;24(1):257–263. doi:10.1093/annonc/mds237
   PubMed Web of Science ®Google Scholar
• Park MS, Ravi V, Araujo DM. Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. Curr Opin Oncol. 2010;22(4):351–355. doi:10.1097/CCO.0b013e32833aaad4
   PubMed Web of Science ®Google Scholar
• Pallotti MC, Nannini M, Agostinelli C, et al. Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma. World J Gastroenterol. 2014;20(22):7049–7054. doi:10.3748/wjg.v20.i22.7049
   PubMed Web of Science ®Google Scholar
• Demir L, Can A, Oztop R, et al. Malignant epithelioid hemangioendothelioma progressing after chemotherapy and Interferon treatment: a case presentation and a brief review of the literature. J Cancer Res Ther. 2013;9(1):125–127. doi:10.4103/0973-1482.110386
   PubMed Web of Science ®Google Scholar
• Soape MP, Verma R, Payne JD, et al. Treatment of hepatic epithelioid hemangioendothelioma: finding uses for thalidomide in a new era of medicine. Case Rep Gastrointest Med. 2015;2015:326795. doi:10.1155/2015/326795
   PubMedGoogle Scholar
• Lakkis Z, Kim S, Delabrousse E, et al. Metronomic cyclophosphamide: an alternative treatment for hepatic epithelioid hemangioendothelioma. J Hepatol. 2013;58(6):1254–1257. doi:10.1016/j.jhep.2013.01.043
   PubMed Web of Science ®Google Scholar
• Stacchiotti S, Provenzano S, Dagrada G, et al. Sirolimus in advanced epithelioid hemangioendothelioma: a retrospective case-series analysis from the Italian rare cancer network database. Ann Surg Oncol. 2016;23(9):2735–2744. doi:10.1245/s10434-016-5331-z
   PubMed Web of Science ®Google Scholar
• Flucke U, Vogels RJ, Somerhausen ND, et al. Epithelioid hemangioendothelioma: clinicopathologic, immunhistochemical, and molecular genetic analysis of 39 cases. Diagn Pathol. 2014;9:131. doi:10.1186/1746-1596-9-131
   PubMed Web of Science ®Google Scholar
• Varelas X. The hippo pathway effectors TAZ and YAP in development, homeostasis and disease. Development. 2014;141(8):1614–1626. doi:10.1242/dev.102376
   PubMed Web of Science ®Google Scholar
• Kyriazoglou A, Zagouri F, Dimopoulos MA. Olaratumab administered in two cases of phyllodes tumor of the breast: end of the beginning? ESMO Open. 2019;4:e000479. doi:10.1136/esmoopen-2018-000479
   PubMed Web of Science ®Google Scholar
• Afrit M, Nasri M, Labidi S, et al. Aggressive primary hepatic epithelioid hemangioendothelioma: a case report and literature review. Cancer Biol Med. 2017;14(2):187–190. doi:10.20892/j.issn.2095-3941.2016.0105
   PubMed Web of Science ®Google Scholar
• Idilman R, Dokmeci A, Beyler AR, et al. Successful medical treatment of an epithelioid hemangioendothelioma of liver. Oncology. 1997;54(2):171–175. doi:10.1159/000227683
   PubMed Web of Science ®Google Scholar